Abstract
PURPOSE OF REVIEW: To review the latest advances in migraine management with a focus on medications specifically developed for the treatment of migraine.
RECENT FINDINGS: Randomized clinical trials demonstrated the efficacy of calcitonin gene-related peptide (CGRP) mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist gepants for acute abortion and prevention of migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is another signaling molecule of interest and represents a potential new drug class of mechanism-based migraine medications. Drugs targeting PACAP are currently undergoing clinical trials, and the coming years will reveal whether this class of drugs will expand our therapeutic armamentarium.
SUMMARY: Here, we summarize the role of CGRP and PACAP in migraine pathophysiology and discuss novel therapies targeting the CGRP and PACAP signaling pathways.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Current Opinion in Endocrinology, Diabetes and Obesity |
| Vol/bind | 29 |
| Udgave nummer | 2 |
| Sider (fra-til) | 225-231 |
| Antal sider | 7 |
| ISSN | 1752-296X |
| DOI | |
| Status | Udgivet - 1 apr. 2022 |